LEADER 04428nam 22006615 450 001 9910298348103321 005 20200703180006.0 010 $a3-662-43604-3 024 7 $a10.1007/978-3-662-43604-2 035 $a(CKB)3710000000228762 035 $a(EBL)1965969 035 $a(OCoLC)890472000 035 $a(SSID)ssj0001353645 035 $a(PQKBManifestationID)11730251 035 $a(PQKBTitleCode)TC0001353645 035 $a(PQKBWorkID)11315597 035 $a(PQKB)10974859 035 $a(MiAaPQ)EBC1965969 035 $a(DE-He213)978-3-662-43604-2 035 $a(PPN)181347458 035 $a(EXLCZ)993710000000228762 100 $a20140904d2014 u| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aMetronomic Chemotherapy $ePharmacology and Clinical Applications /$fedited by Guido Bocci, Giulio Francia 205 $a1st ed. 2014. 210 1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2014. 215 $a1 online resource (302 p.) 300 $aDescription based upon print version of record. 311 $a3-662-43603-5 320 $aIncludes bibliographical references at the end of each chapters. 327 $aPart I: Pharmacological bases of metronomic chemotherapy: The metronomic concept -- Antiangiogenic effects of metronomic chemotherapy -- Effects of metronomic chemotherapy on immunity -- Other proposed mechanism of action of metronomic chemotherapy. Part II: Preclinical studies of metronomic chemotherapy: Alkylating agents -- Camptothecins -- Fluoropyrimidines -- Taxanes -- Vinca alkaloids -- Anthracyclines -- Other drugs -- Part III. Drugs combined with metronomic chemotherapy in preclinical studies: Tyrosine kinase inhibitors -- Monoclonal antibodies -- Tumor vaccines -- Other drugs. Part IV. Clinical activity of metronomic chemotherapy: Breast cancers -- Prostate cancers -- Gastrointestinal cancers -- CNS cancers -- Pediatric malignancies -- Sarcomas -- Hematological cancers -- Liver cancers -- Gynecologic Cancers -- Lung cancers -- Other cancers. Part V: Clinical Pharmacology of metronomic chemotherapy: Pharmacokinetics of metronomic chemotherapy -- Pharmacodynamics of metronomic chemotherapy -- Pharmacogenetics of metronomic chemotherapy -- Pharmacoeconomics of metronomic chemotherapy and its social impact -- Adverse drug reactions of metronomic chemotherapy. Part VI:  Metronomic chemotherapy in veterinarian clinic: Clinical studies of metronomic chemotherapy alone -- Clinical studies of metronomic chemotherapy and other drugs. 330 $aThis book analyzes all aspects of metronomic chemotherapy, a new approach involving low-dose, long-term, and frequently administered therapy that has preclinical and clinical activity in various tumors. After an opening section on the pharmacological bases of metronomic chemotherapy, including its antiangiogenic effects and impact on immunity, preclinical studies on various classes of drug are discussed. Clinical applications of metronomic chemotherapy in a wide variety of tumors are then addressed in detail, with description of the results of all published studies. The clinical pharmacology of metronomic chemotherapy is also considered in depth, encompassing pharmacokinetics, pharmacogenetics, pharmacoenconomics, and adverse drug reactions. The book closes by describing the role of this therapy in the veterinarian clinic. 606 $aPharmacology 606 $aOncology   606 $aCancer research 606 $aPharmacology/Toxicology$3https://scigraph.springernature.com/ontologies/product-market-codes/B21007 606 $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160 606 $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001 615 0$aPharmacology. 615 0$aOncology  . 615 0$aCancer research. 615 14$aPharmacology/Toxicology. 615 24$aOncology. 615 24$aCancer Research. 676 $a610 676 $a614.5999 676 $a615 676 $a616994 702 $aBocci$b Guido$4edt$4http://id.loc.gov/vocabulary/relators/edt 702 $aFrancia$b Giulio$4edt$4http://id.loc.gov/vocabulary/relators/edt 906 $aBOOK 912 $a9910298348103321 996 $aMetronomic Chemotherapy$92512261 997 $aUNINA